Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor-Reference-Cited by-同舟云学术

Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

Published:2011-11-29 Issue:2 Volume:18 Page:510-523
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Liu Xuesong,Shi Yan,Maag David X.,Palma Joann P.,Patterson Melanie J.,Ellis Paul A.,Surber Bruce W.,Ready Damien B.,Soni Niru B.,Ladror Uri S.,Xu Allison J.,Iyer Ramesh,Harlan John E.,Solomon Larry R.,Donawho Cherrie K.,Penning Thomas D.,Johnson Eric F.,Shoemaker Alexander R.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 161 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Treatment of Metastatic Triple‐Negative Breast Cancer: A Systematic Review;The Breast Journal;2024-01

2. PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis;Canadian Journal of Physiology and Pharmacology;2024-01-01

3. PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis;CAN J PHYSIOL PHARM;2023

4. Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation;Cancer Discovery;2023-09-15

5. Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers;OncoTargets and Therapy;2023-07